Condition: Systemic Lupus Erythematosus · Systemic Sclerosis · Inflammatory Myopathy · Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd.
An exploratory clinical study of the safety and efficacy of YTS109 cell injection in subjects with recurrent/refractory autoimmune disease
This description comes directly from the study's public registry record.
Huji Xu · 8602181886999 · xuhuji@smmu.edu.cn
Always discuss trial participation with your own doctor first.
| Shanghai Changzheng Hospital | Shanghai, Shanghai Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06379646